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a b s t r a c t
Identiﬁcation of antigenic variants is the key to a successful inﬂuenza vaccination program. The
empirical serological methods to determine inﬂuenza antigenic properties require viral propagation.
Here a novel quantitative PCR-based antigenic characterization method using polyclonal antibody and
proximity ligation assays, or so-called polyPLA, was developed and validated. This method can detect a
viral titer that is less than 1000 TCID50/mL. Not only can this method differentiate between different HA
subtypes of inﬂuenza viruses but also effectively identify antigenic drift events within the same HA
subtype of inﬂuenza viruses. Applications in H3N2 seasonal inﬂuenza data showed that the results from
this novel method are consistent with those from the conventional serological assays. This method is not
limited to the detection of antigenic variants in inﬂuenza but also other pathogens. It has the potential to
be applied through a large-scale platform in disease surveillance requiring minimal biosafety and
directly using clinical samples.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The inﬂuenza virus is a perpetual threat to public health.
Seasonal inﬂuenza infections are associated with thousands of
deaths every year in the United States (Thompson et al., 2010). A
worldwide pandemic could increase the death toll to millions in a
short period of time. The hallmark of the inﬂuenza virus is
antigenic variation, which comes in two forms: antigenic drift
and antigenic shift, leading to the recurrence of inﬂuenza virus
infections (Katz et al., 1987). Mutations in the hemagglutinin and
neuraminidase glycoproteins cause antigenic drift. Meanwhile,
antigenic shift is caused by the replacement of a new subtype of
hemagglutinin and sometimes neuraminidase through genetic
reassortment.
The inﬂuenza vaccine is the most viable option in counteracting
and reducing the impact of inﬂuenza outbreaks (Harper et al., 2004).
Since inﬂuenza viruses are continuously changing their antigenicity
in order to escape the host immunity (Nobusawa and Nakajima,
1988; Webster et al., 1982), the vaccine strains need to be updated
almost annually to obtain antigenic matches between the vaccine
strain and the strain potentially causing future outbreaks (Ampofo
et al., 2012; Gerdil, 2003). Identiﬁcation of inﬂuenza antigenic
variants is the key to a successful inﬂuenza vaccination program
for both pandemic preparedness as well as seasonal inﬂuenza
prevention and control (Katz et al., 1987).
Routinely, immunological tests, such as hemagglutination inhibi-
tion (HI) assays and microneutralization (MN) assays, have been
relied upon to identify antigenic variants among the circulating
strains (Medeiros et al., 2001). The HI assay is an experiment to
measure how a test inﬂuenza antigen and a reference antigen (e.g. a
current vaccine strain) match through the immunological reaction
between the test antigen and the reference antiserum. This reference
antiserum is usually generated in ferrets using the reference antigen.
HI assays are limited due to their use of red blood cells (RBCs), e.g.
turkey red blood cells, as indicators for the binding afﬁnity of antigen
and antiserum (Kendal et al., 1982). A higher interaction between
antigen and antisera will lead to less hemagglutination of RBCs (Hirst,
1941). Compared to HI assays, MN assays seem to be more sensitive
and speciﬁc but are much more time-consuming. Moreover, for
inﬂuenza viruses requiring biosafety-level 3 (BSL-3) or higher, MN
assays are difﬁcult to perform (Grund et al., 2011). For this reason, HI
assays have been one of the routine procedures used to identify
inﬂuenza antigenic variants for vaccine strain selection while MN
assays are generally used to validate the results from HI assays.
However, the data from HI assays are notoriously noisy, and HI
experiments are affected by many factors. For example, RBCs used
from different species and even variation in RBC sialic acid receptors
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can produce varied results (Medeiros et al., 2001). The data are
subjective interpretations and the HI assays have difﬁculty in
automating and standardizing operations. Minor antigenic variants
within a heterogeneous population cannot be assessed by the
serological method of HI (Patterson and Oxford, 1986). More
importantly, mutations of the receptor binding site in HA
(Nobusawa and Nakajima, 1988) (antigenic drift) are causing human
seasonal H1N1 (Azzi et al., 1993; Morishita et al., 1993) and H3N2
inﬂuenza A viruses (Nobusawa et al., 2000) to lose the ability to
bind to RBCs. For example, the mutations at residues 193, 196, 197,
and 225 in the human epidemic H1N1 inﬂuenza A viruses in 1988
or later caused the loss of their abilities to agglutinate chicken RBCs
due to four amino acid changes (Morishita et al., 1996). For H3N2
viruses, the Gly190Asp substitution has been correlated to the loss
of the ability to agglutinate chicken erythrocytes (Cox and Bender,
1995; Fitch et al., 1997; Lindstrom et al., 1998, 1996; Medeiros et al.,
2001; Mori et al., 1999; Nobusawa et al., 2000). Since 2000, human
seasonal H1N1 and H3N2 inﬂuenza A viruses have been losing their
binding abilities to turkey red blood cells (Medeiros et al., 2001; Oh
et al., 2008). This may be attributed to a reduced afﬁnity for sialic
acid-linked receptors (particularly α2-6-linked receptors), which are
at lower levels on chicken and turkey RBC compared to levels on
guinea pig RBC (Medeiros et al., 2001; Oh et al., 2008). Conse-
quently, a critical demand exists for the development of a red blood
cell independent assay for inﬂuenza antigenic variation.
Proximity ligation assay utilizes quantitative real time PCR
(qRT-PCR) for the detection of antigen–antibody interaction
(Schlingemann et al., 2010). For this assay: (1) oligonucleotide-
linked monoclonal antibodies are incubated with the analyte in
question; (2) if in close proximity, the oligonucleotides can be
ligated together; and (3) presence of analyte will be shown by
ampliﬁcation of ligated products with qRT-PCR. The assay reporter
signal is dependent on a proximal and dual recognition of each
target analyte providing high speciﬁcity (Fredriksson et al., 2007).
In this study, we developed a novel antigenic characterization
method using polyclonal antibody-based proximity ligation assays
(polyPLA). This method was found to be useful in detecting
inﬂuenza antigenic variants in clinical samples.
Results
PolyPLA for inﬂuenza antigenic variant detection
PolyPLA quantiﬁes the antibody antigen binding avidity using the
ampliﬁcation signals in quantitative PCR (qPCR) from the pairs of
primers attached to a reference polyclonal antiserum. The ﬁrst step of
this experiment is to biotinylate a reference polyclonal antiserum
(Fig. 1A), which will be then labeled with sodium azide-linked 50 and
30 oligonucleotides (Fig. 1B). The ligation efﬁciency will be assessed
with qPCR. A labeled polyclonal antiserum with ΔCtZ8.5 in the
ligation efﬁciency test is then incubated with a reference antigen
(virus) or a testing antigen (Fig. 1C), followed by the proximity
ligation of the two oligos (Fig. 1D). The antibody antigen binding
avidity is quantiﬁed using the ampliﬁcation signals ΔCt in qPCR
(Fig. 1E). The ΔCt values among the polyclonal antisera and antigens
can be compared to assess antigenic differences among these tested
antigens. These ΔCt values can be viewed as similar to the serological
titers, such as HI and neutralization titers, from conventional
serological assays (Fig. 1F).
To make the ΔCt values comparable across reference sera, we have
to ensure that the testing antigens have the same quantities across
quantiﬁcation assays. In HI assays, we usually standardize the antigens
to be 4 units of hemaglutinnation titer before HI; in neutralization
assays, we usually standardize antigen quantities using TCID50 (2013).
In this assay, we use the quantities of nucleoproteins (NPs) to
normalize the amount of viruses in the analyses. For data consistency,
we used a monoclonal antibody targeting conserved regions of NPs in
the proximity ligation assay (Schlingemann et al., 2010). Thus, for a
testing antigen, the polyPLA units were normalized by its ΔCt values
for polyclonal antiserum (polyΔCt) with its ΔCt values for monoclonal
antibody against NP (monoΔCt) (Fig. 1G).
Viral particles must be completely lysed to release NPs and
allow for an accurate measure of these protein quantities. We
compared two commonly used methods for viral lysis: freeze/
thaw and treatment with lysis buffer. The results showed that lysis
buffer treated virus had a signiﬁcantly higher ΔCt value of 7.46 (7
0.45) for A/Sydney/05/1997 (SY/05), po0.05 (Fig. 2) compared to
the freeze/thaw method of viral lysis. However, for A/Sichuan/2/
1987 (SI/2), lysis buffer treated virus did not have a signiﬁcantly
different ΔCt value compared to that of the freeze/thaw method of
viral lysis. In the following assays, all the samples used in normal-
ization were treated with lysis buffer.
HA speciﬁc IgG predominates polyclonal antisera
PolyPLA quantiﬁes the interactions between inﬂuenza viral pro-
teins and all IgG present in the polyclonal antisera. To assess the
impacts of NA and other internal proteins on polyPLA, we constructed
three reassortants between SY/05 and PR8, including SY/05xPR8
(H3N2), SY/05xPR8(H3N1), and SY/05xPR8(H1N2). The signals from
NPC were used as the control to calculate ΔCt value from proximity
ligation assays. Our results showed that SY/05, SY/05xPR8(H3N2), and
SY/05xPR8(H3N1) had ΔCt values of 5.40(7 0.74), 5.67(7 0.17), and
5.26(7 0.34), respectively (Fig. 3). The ΔCt values from PR8 and the
reassortant SY/05xPR8(H1N2) were negligible.
Viral quantities are linearly correlated with ΔCt values
To assess the sensitivity of polyPLA, we performed PLA on inﬂuenza
A viruses with serial dilutions. Regression analyses demonstrated that
the polyΔCt values are linearly correlated with the inﬂuenza viral
quantities, with Pearson's coefﬁcient R¼0.98 for the testing strain SY/
05 (po0.001) (Fig. 4). The cutoff ΔCt value 3.00 was equivalent to
4.90104 TCID50/mL against its homologous polyclonal antibodies.
Similarly, the mono-ΔCt values were also linearly correlated with HA
titers, and the R was 0.92 for SY/05 (po0.001). The cutoff ΔCt value
was equivalent to 9.80104 TCID50/mL against the NP-speciﬁc
monoclonal antibody. Similar linear correlations were also observed
in A/Johannesburg/33/1994(H3N2) (JO/33) and A/Nanchang/933/1995
(H3N2) (NA/933) (data not shown). Linear correlation between viral
quantities and ΔCt allows us to normalize the viral titers by using a
simple equation such as a (polyΔCtmonoΔCt)þb, where a and b
are constant parameters. This normalization method enables us to
compare the antigenic properties between the testing antigens
(viruses) without justifying the viral quantities before measuring
polyΔCt, having been used in HI and neutralization assays to ensure
the equivalency of the viral quantities before assays.
Sensitivities of polyPLA
To test the sensitivity of polyPLA, we evaluated the viral loads from
nasal swabs collected from ferrets infected with A/swine/K6/2011
(H6N6). After only the ﬁrst day of infection, a polyΔCt titer of 3.20
(70.06, standard deviation) was obtained, corresponding to a TCID50
titer of 1.00103 for the infected ferret (Fig. 5). After two days of
infection, a polyΔCt value of 5.19 (70.06) was obtained, correspond-
ing to a TCID50 titer of 1.00104. A higher polyΔCt titer corresponded
to a higher TCID50 titer among the nasal wash samples post-infection.
All the samples collected from the control ferrets had polyΔCt titers of
less than 3.00, and no viruses were recovered from these control
ferrets (Fig. 5). Thus, this method is sensitive sufﬁciently to detect not
B.E. Martin et al. / Virology 476 (2015) 151–158152
Fig. 2. Optimization of the methods in detecting NP proteins using proximity
ligation assays. OV denotes the control the control viruses, which were harvested
directly after viral propagation in MDCK cells; F–T denotes the viruses, which were
frozen and thawed 5 times; L denotes the viruses, which were treated with lysis
buffer.
Fig. 3. PolyPLA detects predominant IgG against HA gene. The ΔCt of proximity
ligation assays for SY/05(H3N2), PR8(H1N1), and three reassortants SY05xPR8
(H3N2), SY05xPR8(H1N2), and SY05xPR8(H3N1) were measured using reference
polyclonal sera against SY/05(H3N2).
Fig. 4. The linear correlation of polyΔCt (R¼0.98) and monoΔCt (R¼0.92) with
viral quantities. The cutoff ΔCt value 3.00 was equivalent to 4.90104 TCID50/mL
against its homologous polyclonal antibodies and 9.80104 TCID50/mL against NP
speciﬁc monoclonal antibody.
Fig. 5. Sensitivity of polyPLA. Comparison of polyΔCt and monoΔCt titers with viral
culture titers using the nasal swabs collected from the ferrets infected with A/
swine/Guangdong/K6/2010(H6N6). After only the ﬁrst day of infection, a polyΔCt
value of 3.20 (70.06, standard deviation) was obtained, corresponding to a TCID50
titer of 1.00103 for the infected ferret. After two days of infection, a polyΔCt value
of 5.19 (70.06) was obtained, corresponding to a TCID50 titer of 1.00104.
Fig. 1. The simpliﬁed diagram of polyPLA. PolyPLA quantiﬁes the antibody antigen binding avidity using the ampliﬁcation signals in quantitative PCR (qPCR) from the pairs of
primers attached to a reference polyclonal antiserum. First, polyPLA biotinylates a reference polyclonal antiserum (A), which will be then labeled with sodium azide-linked 50
and 30 oligonucleotides (B). A labeled polyclonal antiserumwith ΔCtZ8.5 in the ligation efﬁciency test is then incubated with a reference antigen (virus) or a testing antigen
(C), followed by the approximate ligation of the two oligos (D). The antibody antigen binding avidity is quantiﬁed using the ampliﬁcation signals ΔCt in qPCR (E). The ΔCt
values among the polyclonal antisera and antigens can be compared to assess antigenic differences among these tested antigens, and these ΔCt values can be viewed as
similar as the serological titers, such as HI and neutralization titers, from conventional serological assays (F). The polyPLA units were normalized by its ΔCt values for
polyclonal antiserum (polyΔCt) with its ΔCt values for monoclonal antibody against NP (monoΔCt) (G).
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only the viruses propagated from the laboratory, but also those in
animal specimens. The detection limit is approximately 103 TCID50/
mL, which is much less than the viral loads from most patients at the
peak time of virus shedding. For example, man can shed 2.6, 5.0, 5.1,
4.9, 3.8, and 1.9 TCID50/mL from one through six days post-
inoculation of H1N1 seasonal inﬂuenza virus, respectively (Baccam
et al., 2006).
Detecting antigenic variants of H3N2 historical seasonal inﬂuenza
viruses
The H3N2 viruses have been causing seasonal epidemic outbreaks
since its ﬁrst introduction into the human population, resulting in the
pandemic of 1968. During the past four decades, at least 12 antigenic
drift events have been detected; six of which occurred from 1997 to
2010 (Skowronski et al., 2007; Sun et al., 2013). In this study, six
historical H3N2 isolates, JO/33, NA/933, SY/05, A/Brisbane/10/2007
(BR/10), A/Perth/16/2009 (PE/16), and A/Victoria/361/2011(VI/361)
representing antigenic cluster BE92, WU95, SY97, BR07, PE09, and
VI11 (Sun et al., 2013), respectively, and their corresponding homo-
logous ferret antisera were used to validate polyPLA. Our method was
expected to identify signiﬁcant differences in homologous and hetero-
logous polyPLA titers (Table 1).
Our results showed that the homologous titers were approxi-
mately 10.00 polyPLA units. The polyPLA titers for NA/933 and SY/05
against JO/33 antisera were 9.37 (70.22) and 6.725 (70.32) polyPLA
units, respectively, which were signiﬁcantly less than the homolo-
gous JO/33 titer 11.43 (70.01) units, po0.0001 (Fig. 6A, Table 2). The
homologous titer for NA/933 was 11.71 (70.28) whereas the titers
for JO/33 and SY/05 against NA/933 antisera were 8.44 (70.32) and
8.16 (70.43) units, respectively; the titers for JO/33 against NA/933
antisera were signiﬁcantly less than the homologous titers for JO/33,
po0.001. The homologous titer for SY/05 was 13.19 (70.06) units
whereas the titers for JO/33 and NA/933 against SY/05 antisera were
10.59 (70.15) and 8.21 (70.07) units, respectively; the titers for
both JO/33 and NA/933 against SY/05 antisera were signiﬁcantly less
than the homologous titers for SY/05, po0.0001.
Similarly, the homologous titers for BR/10 were 9.91 (70.16)
whereas the titers for PE/16 and VI/361 against BR/10 sera were
7.97 (70.12) and 7.72 (70.21), respectively (Fig. 6B); the titers for
PE/16 and VI/361 against BR/10 sera were signiﬁcantly less than
the homologous titers for BR/10, po0.001. PE/16 had the highest
polyΔCt value of 12.00 (70.20) against PE/16 sera whereas the
titers for BR/10 and VI/361 against PE/16 sera were 7.92 (70.10)
and 10.01 (70.15), respectively; the titers for BR/10 and VI/361
against PE/16 sera were signiﬁcantly less than the homologous
titers for PE/16, po0.001. The homologous titer for VI/361 was
10.87 (70.22) whereas the titers for BR/10 and PE/09 against
VI/361 sera were 5.90 (70.10) and 7.93 (70.15), respectively; the
titers for BR/10 and PE/09 against VI/361 sera were signiﬁcantly
less than the homologous titers for VI/361, po0.001.
Detecting antigenic variants in human clinical specimens
To test the applicability of polyPLA in clinical samples, we
applied the same method to characterize antigenic proﬁles of
H3N2 inﬂuenza A viruses, which came directly from clinical
samples collected in the 2012–2013 inﬂuenza season. A total of
100 nasal swabs were collected from September 2012 to April
2013, and conﬁrmed as H3N2 positive using quantitative RT-PCR.
About 50% of these samples had at least a 3-polyPLA-unit
decrease compared to BR/10 homologous titers and that about 18%
and 1% of these samples had at least 3-polyPLA-unit decrease
when compared to PE/16 and VI/361 homologous titers, respec-
tively (Fig. 7A). The polyPLA titers of the majority clinical samples
were highest when using VI/361 sera, followed by PE/16 and BR/
10. We compared the polyΔCt titers of the clinical samples with
the HI titers for these 21 isolates, and the HI titers were positively
correlated with polyΔCt titers (Fig. 7B).
To better understand the antigenic and genetic background of
the H3N2 viruses in these samples, 21 samples were randomly
selected and subjected to viral isolation using MDCK cells. A total
of 21 viruses were recovered, and the HA sequences of these
viruses were sequenced. The sequence analyses showed that no
consistent mutations at the reported antibody binding sites
(Wilson and Cox, 1990) were observed in the isolates we recovered
from this study (Table 4).
Since 2007, the H3N2 seasonal inﬂuenza viruses have six
genetic clusters (2013). The genetic clusters 1 and 2 were PE/16
like-viruses. The viruses from 2010 were scattered into genetic
clusters 3, 4, 5, and 6. The phylogenetic analyses showed that these
21 viruses belonged to genetic cluster 3C and 5 (Fig. 7C).
Discussion
Identiﬁcation of antigenic variants in disease surveillance is
essential, and an ideal antigenic characterization platform should
meet the following four criteria: (1) robust, the results should be
repeatable; (2) simple and economic, the methods can be carried
out in a common diagnosis laboratory; (3) high throughput, the
method should be able to perform on a large-scale; and (4) sensitive,
the method will have optimal performance in identifying antigenic
variants directly from clinical samples, avoiding viral isolation. For
many diseases, the pathogen isolation process is not only time-
consuming but also can change virus antigenic properties, resulting
in data that does not accurately represent those antigenic properties
in circulating viruses. Furthermore, some pathogens cannot even be
recovered from the specimen. The polyPLA developed in this study
was designed to meet these four criteria, as conﬁrmed in inﬂuenza
antigenic variant identiﬁcation in this study.
The polyPLA quantiﬁes antibody antigen interactions for inﬂu-
enza viral proteins, including both HA and NA, against their
corresponding antibodies in the antisera. The principle of this
method is more similar to neutralization assays rather than HI
assays. More importantly, it can avoid the red blood cell binding
problems usually seen in HI assay. For example, egg-adaptation
substitutions affect the architecture of the HA receptor-binding
site and alter the interactions of the HA with the terminal sialic
acid moiety (Gambaryan et al., 1999).
The high concentration of inﬂuenza A viruses could lead to the
saturation of viruses over antibody, which is 200 nM used in this
study. For example, when the undiluted, MDCK cell derived NA/
933 virus was used, there was no signiﬁcant difference between
the ΔCt values against NA/933 antibody and those against JO/33
antibody (data not shown). After the NA/933 viruses were diluted
to 1:40, there was signiﬁcant difference between the ΔCt values
against NA/933 and those against JO/33 antibodies (Tables 2 and 3
Table 1
The H3N2 inﬂuenza A viruses used in this study.
Virus Abbreviation Antigenic clustera
A/Sichuan/2/87(H3N2) SI/2 ND
A/Johannesburg/33/94(H3N2) JO/33 BE92
A/Nanchang/933/95(H3N2) NA/933 WU95
A/Sydney/05/97(H3N2) SY/05 SY97
A/Brisbane/10/07(H3N2) BR/10 BR07
A/Perth/16/09(H3N2) PE/16 PE09
A/Victoria/361/11(H3N2) VI/361 VI11
a The antigenic cluster was described in Sun et al. (2013), and ND¼not
determined.
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and Fig. 6). However, we do not believe this potential limitation
will affect the application of this method in clinical samples, from
which the virus loads are much smaller than a single isolate.1
Compared to seasonal inﬂuenza virus surveillance, the anti-
genic characterization of emerging pathogens for pandemic pre-
paredness, especially those pathogens in areas without sufﬁcient
Fig. 6. Detecting antigenic variants of H3N2 historical seasonal inﬂuenza viruses. JO/33, NA/933, SY/05, BR/10, PE/16, VI/361 representing antigenic cluster BE92, WU95, SY97,
BR07, PE09, and VI11, respectively. The homologous polyPLA titers were signiﬁcantly higher than the heterologous titers for both the antigenic drift event
BE924WU954SY97 (A) and BR074PE094VI11(B). These results were consistent with those measured from conventional HI and neutralization assays (Tables 2 and 3).
Fig. 7. Detecting antigenic variants in human clinical specimens. (A) The percentile of antigenic variants (white portion) compared to their corresponding homologous titers,
and a 3-polyPLA-unit threshold was used; (B) the correlation between polyPLA units and HI titers, which was measured using PE/16 polyclonal antisera; (C) phylogenetic tree
of HA protein sequences of H3N2 seasonal inﬂuenza viruses. The 21 isolates recovered from the 2012–2013 inﬂuenza season from Mississippi were marked in red, and the
antigenic variants proposed by polyPLA assays using clinical samples against PE/16 were marked with stars. The phylogenetic tree was constructed by maximum parsimony
based on HA protein sequences, and genetic clusters were deﬁned based on the reports from Community Network of Reference Laboratories (CNRL) for Human Inﬂuenza in
Europe (http://www.ecdc.europa.eu/en/publications/Publications/Inﬂuenza-visus-characterisation-June-2012.pdf).
B.E. Martin et al. / Virology 476 (2015) 151–158 155
biosafety facilities, has been challenging. Propagation of these
emerging viruses usually requires a high biosafety containment
such as BSL-3 and even BSL-4. In most cases, the specimens need
to be shipped to a laboratory with appropriate biosafety contain-
ment, and sometimes even the paperwork for collaborative
agreements, especially among countries, can cause delays when
an outbreak occurs. Because the polyPLA can use the clinical
samples directly and also use a common qRT-PCR platform, it
can perform large-scale analyses with minimal biosafety require-
ments in laboratory conditions. For example, biosafety level 2 will
meet for the polyPLA in inﬂuenza surveillance (Engelhardt et al.
2013). Thus, this method will be very useful in detecting antigenic
variants for the H5N1 highly pathogenic avian inﬂuenza viruses
and emerging H7N9 low pathogenic avian inﬂuenza viruses. In
resource limited areas, although the RBCs in conventional serolo-
gical assays such as HI can be more accessible, it would be much
easier and economic to set up a qRT-PCR platform than a high
containment environment for viral propagation.
In summary, polyPLA is a simple method quantifying the
binding avidity of antibody antigen interactions. Beyond inﬂuenza
applications, this method can also be used in other pathogens
including those cannot be propagated in laboratory.
Materials and methods
Viruses and antibodies
The H3N2 viruses used in this study were obtained from the
Centers of Disease Control and Prevention, Department of Health &
Human Services and BEI Research Resources Repository (http://
www.beiresources.org/) (Table 1), and the monoclonal antibodies
against nucleoprotein (NP) from Millipore, United States. The viruses
were propagated at Madin–Darby Canine Kidney (MDCK) cells and
stored at 80 1C before usage. The polyclonal antisera were gener-
ated using 4- to 6-month-old ferrets (Triple F Farm, PA). The ferrets
were anesthetized with isoﬂurane and inoculated intranasally with
106 50% egg infectious doses (EID50) of a challenging virus. The ferret
sera were collected three weeks post-infection. The viral isolation
was performed using MDCK cells.
Labeling of antibodies
IgG were puriﬁed from ferret polyclonal antisera and mice
monoclonal antibodies using Pierce Chromatography Cartridges
Protein A/G according to the manufacturer's instruction (Pierce,
Rockford, IL) and then biotinylated with Biotin-XX Microscale
Protein Labeling Kit according to manufacturer directions (Life
Technologies, Carlsbad, CA). To remove the free biotin, Slide-A-
Lyzer Dialysis Cassettes (Thermo Scientiﬁc Pierce, Rockford, IL)
were used; dialysis was performed at 4 1C in cold 1X PBS (pH 7.4),
and the buffer was changed at least 5 times each 2 h.
Forced proximity probe test
An aliquot of biotinylated antibody stock solution was diluted
to 200 nM (30 mg/mL); 2 mL of diluted biotinylated antibody was
added to 2 mL of equal mixture of 200 nM 30 and 50 TaqMan Prox-
Oligo, designated probe A and probe B (Life Technologies, Carlsbad,
CA), and incubated at room temperature for 60 min. A negative
control was made replacing diluted biotinylated antibody with
2 mL antibody dilution buffer. After incubation, 396 mL of assay
probe dilution buffer was added and incubated for another 30 min
at room temperature. Then 96 mL of ligation solution was added to
4 mL of the probe and virus mixture, incubated again at 37 1C for
10 min, and cooled at 4 1C for 10 min. After incubation, 9 mL was
transferred to a new 0.2 mL microcentrifuge tube with 11 mL qPCR
mix (10 mL Fast Master Mix, 2X plus 1 mL Univeral PCR Assay, 20X)
and was brieﬂy centrifuged. The qPCR cycling was as follows: 95 1C
for 2 min, 40 cycles of 95 1C for 15 s, and 60 1C for 1 min.
The change in threshold cycle (ΔCt) values was calculated for
each biotinylated antibody: average Ct (negative control)average
Ct (forced proximity probe). If the ΔCtZ8.5, the test biotinylated
antibody was considered suitable for use in the PLA.
Table 2
The correlation among the titers from polyPLA and those from HI and MN assays for JO/33, NA/33, and SY/05.
Virus Ferret antiseraa
JO/33 NA/933 SY/05
HI MN PolyΔCt (standard deviation) HI MN PolyΔCt (standard deviation) HI MN PolyΔCt (standard deviation)
JO/33 640 ND 11.43 (0.01) 40 ND 8.44 (0.32) o10 40 10.59 (0.15)
NA/933 160 ND 9.37 (0.22) 1280 ND 11.71 (0.28) 160 30 8.21 (0.07)
SY/05 o10 ND 6.725 (0.32) o10 ND 8.16 (0.43) 1280 1280 13.29 (0.06)
a The number in bold is the homologous titer.
Table 3
The correlation among the titers from polyPLA and those from HI and MN assays for BR/10, PE/16, and VI/361.
Virus Ferret antiseraa
BR/10 PE/16 VI/361
HI MN PolyΔCt (standard deviation) HI MN PolyΔCt (standard deviation) HI MN PolyΔCt (standard deviation)
WI/67 ND ND 40 160 320 320
BR/10 1280 2560 9.91(0.16) 40 160 7.92(0.10) 40 40 5.90(0.10)
PE/16 80 80 7.97(0.12) 640 640 12.00(0.20) 160 160 7.93(0.15)
VI/361 20 20 7.72(0.21) 320 640 10.01(0.15) 640 640 10.87(0.22)
a The number in bold is the homologous titer.
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Probe preparation
Two assay probes for each antibody were prepared by combin-
ing the biotinylated antibodies with either 30 or 50 TaqMan Prox-
Oligo (probe A and probe B). For example, for each probe, 2.5 mL
200 nM biotinylated antibody was combined with 2.5 mL of either
200 nM 30 prox-Oligo or 200 nM 50 prox-Oligo, and the mixture
was incubated at room temperature for 60 min. Then, 45 mL Assay
Probe Storage Buffer was added, brieﬂy centrifuged, and incubated
at room temperature for 20 min.
PLA and quantiﬁcation of polyΔCt and monoΔCt
The Taqman PLA was performed by ﬁrst diluting equal parts of
probes A and B mixture 1:10 with phosphate-buffered saline (PBS,
pH 7.4). For the non-protein control (NPC), 2 mL was combined
with 2 mL diluted virus (virus lysed for NP detection) or 2 mL 1X
PBS, pH 7.4. The mixture was centrifuged brieﬂy and incubated at
37 1C for 1 h. Then, 96 mL of ligation solution was added to 4 mL of
the probe and virus mixture, incubated again at 37 1C for 10 min,
and cooled at 4 1C up to 10 min. After incubation, 2 mL of 1X
protease was added to each ligation reaction and incubated at
37 1C for 10 min, 95 1C for 5 min, and 4 1C for holding. Lastly, 9 mL
of the product was transferred to a new 0.2 mL microcentrifuge
tube with 11 mL qPCR mix (10 mL Fast Master Mix, 2X plus 1 mL
Univeral PCR Assay, 20X) and was brieﬂy centrifuged. The qPCR
cycling was as follows: 95 1C for 2 min, 45 cycles of 95 1C for 15 s,
and 60 1C for 1 min.
The NPC was used as a reference background and the threshold
cycle (Ct) value given dictated the non-target ligation signal noise
of the assay. A total of three replicates for each sample and control
were performed. To calculate the ΔCt values: average Ct (NPC)
average Ct (sample), which represented the true target-mediated
signal above background. The cutoff of ΔCtZ3.00 was used for
qualitative analysis of viral and antibody binding, as according to
the Taqman Protein Assays Sample Prep and Protocol (2013).
HI and virus neutralization assays
In the HI assay, the receptor destroying enzyme (RDE, Denka
Seiken Co., Japan) was used to treat the ferret sera in the ratio of 1:3
(RDE: sera, volume: volume) for 18 h at 37 1C, then heat inactivated
at 56 1C for 30 min. The treated ferret sera were diluted to 1:10 with
phosphate-buffered saline (PBS) then 2-fold serial diluted and
reacted with 4-hemmagglutination-units viruses. The HI titers were
expressed as the reciprocal of the highest dilution at which virus
binding to the 0.5% turkey red blood cells (RBC) was blocked.
For the virus neutralization assay, serially diluted ferret sera
were ﬁrst incubated with 100 TCID50 viruses at 37 1C for 1 h. The
virus–sera mixtures were then adsorbed to MDCK cells for 1 h. The
infected cells were washed twice with PBS buffer and replenished
with Opti-Mem Reduced Serum Media (Life Technologies, US). The
supernatants from the infected cells were harvested 4 days post-
infection and were analyzed using hemagglutination assay.
Data analysis
To compare the antigenic properties across the testing antigens
(viruses), we computed the polyPLA unit between antigen (virus)
and antibody using the following equation:
polyPLA¼ a ðpolyΔCtmonoΔCtÞþb
To improve our computation, we simply used a¼1.00 and
b¼10.00. The b¼10.00 enabled us to avoid negative numbers. If
monoΔCto3.00, polyPLA will be assigned as “o0”, meaning that
the viral loads were too low for analyses. As mentioned above, in
general, polyPLA is sensitive in detecting viral loads of approxi-
mately 103 TCID50/mL.
Genomic sequencing and Genbank accession number
The HA genes of 21H3N2 isolates recovered from human
clinical specimens were sequenced using Sanger Sequencing, and
Table 4
Molecular characterization of amino acid changes in the HA1 proteins of H3N2 isolates recovered from 2012–2013 season.
Isolate Amino acid positiona
2 8 33 45 (C) 48 (C) 53 (C) 94 (E) 128 (B) 142 (A) 144 (A) 145 (A) 158 (B) 198 (B) 199 223 278 (C) 280 (C) 312 (C)
WI/67 K N Q S T D Y T R N N K A S I N E N
BR/10 K N Q S T D Y T R N N K A S V N E N
PE/16 K N Q S T D Y T R K N N A S V N E N
VI/361 K N Q N I D Y T R N N N S S I N E S
TX/50 K N R N I D Y N R N N N P S I K E S
MS/3 K N R N I D Y T R N S N S S I K E S
MS/4 K N R N I D Y A G N S N S S I K E S
MS/17 K N R N I D Y A G N S N S S I K E S
MS/20 K N R N I D Y T R N S N S S I K E S
MS/27 N N R N I D Y T R N S N S S I K E S
MS/29 K N R N I D Y T R N S N S S I K E S
MS/32 K N R N I D Y T R N S N S S I K E S
MS/33 K N R N I D Y T R N S N S S I K E S
MS/35 E D Q S T N H T R N N N A S V N A N
MS/36 E D Q S T N H T R N N N A S V N A N
MS/40 E D Q S T N H T R N N N A S V N A N
MS/41 K N R N I D Y T R N S N S S I K E S
MS/44 E D Q S T N H T R N N N A S V N A N
MS/45 E D Q S T N H T R N N N A S V N A N
MS/47 E D Q S T N H T R N N N A S V N A N
MS/48 E D Q S T N H T R N N N A S V N A N
MS/49 E D Q S T N H T R N N N A S V N A N
MS/51 E D Q S T N H T R N N N A S V N A N
MS/53 E D Q S T N H T R N N N A S V N A N
MS/65 K N R N I D Y T R N S N S S I K E S
MS/6 E D Q S T N H T R N N N A S V N A N
a The antibody binding sites were annotated based on previous report (Wilson and Cox, 1990).
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they were deposited in Genbank with the accession numbers
KM244531–KM244551.
Molecular characterization and phylogenetic analyses
The multiple sequence alignments were conducted using the
MUSCLE software package (Edgar, 2004). The phylogenetic ana-
lyses were performed using maximum likelihood by GARLI version
(Zwickl, 2006), and bootstrap resampling analyses were conducted
with 1000 runs using PAUPn 4.0 Beta (Swofford, 1998) with a
neighborhood joining method, as previously described (Wan et al.,
2008) (Table 4).
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